WASHINGTON (dpa-AFX) - AbbVie's (ABBV) once-daily formulation of VIEKIRA PAK
to treat genotype 1 chronic hepatitis C virus infection has won FDA approval.
Initially approved in December 2014, VIEKIRA PAK has all along been taken twice
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.